Literature DB >> 11849434

Selective inhibition of inducible nitric oxide synthase enhances intraglomerular coagulation in chronic anti-Thy 1 nephritis.

Ralf Westenfeld1, Alexander Gawlik, Emile de Heer, Masashi Kitahara, Faikah Abou-Rebyeh, Juergen Floege, Markus Ketteler.   

Abstract

BACKGROUND: A particular Lewis rat substrain (LEW/Maa) develops chronic glomerulonephritis in the anti-Thy 1 model (aThy 1-GN) characterized by increased microaneurysm formation, chronic glomerular sclerosis and persistent albuminuria. This phenotype is accompanied by increased and prolonged glomerular induction of inducible nitric oxide synthase (iNOS) when compared to the LEW/Moe substrain, in which aThy 1-GN resolves quickly. We investigated the effect of selective iNOS inhibition by l-N6-(1-iminoethyl)-lysine (L-NIL) administration on aThy 1-GN in LEW/Maa rats.
METHODS: Nephritic rats were studied over a period of 7 days. L-NIL-treated animals received 20 mg/day L-NIL in the drinking water starting two days prior to disease induction. iNOS activity was determined in cultured glomeruli and in urine samples, respectively. Severity of aThy 1-GN was determined by scoring glomerular matrix expansion and microaneurysm formation, and by albuminuria measurements (ELISA). Immunohistochemical evaluation was performed including staining for macrophages (ED-1), platelets (PL-1) and fibrin deposition.
RESULTS: L-NIL treated rats (+NIL) showed a significant decrease in peak nitrate production by ex vivo cultured glomeruli, and in urinary nitrate excretion versus untreated nephritic rats (-NIL). Mean arterial pressure remained unchanged in both +NIL and -NIL rats. +NIL rats developed significantly increased albuminuria (+44%) associated with a significant increase in glomerular platelet (+45%) and fibrin deposition (+48%).
CONCLUSIONS: Selective inhibition of iNOS aggravated albuminuria in chronic aThy 1-GN in LEW/Maa rats. Induction of iNOS during the inflammatory phase of this model may be a partially protective mechanism by interfering with intraglomerular coagulation processes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11849434     DOI: 10.1046/j.1523-1755.2002.00229.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  6 in total

1.  Nitric oxide is an important mediator of renal tubular epithelial cell death in vitro and in murine experimental hydronephrosis.

Authors:  Tiina Kipari; Jean-Francois Cailhier; David Ferenbach; Simon Watson; Kris Houlberg; David Walbaum; Spike Clay; John Savill; Jeremy Hughes
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 2.  Oxidant Mechanisms in Renal Injury and Disease.

Authors:  Brian B Ratliff; Wasan Abdulmahdi; Rahul Pawar; Michael S Wolin
Journal:  Antioxid Redox Signal       Date:  2016-04-26       Impact factor: 8.401

Review 3.  COVID-19 associated thromboinflammation of renal capillary: potential mechanisms and treatment.

Authors:  Xiaojing Chen; Chengyuan Yu; Haijiao Jing; Chunxu Wang; Xinyi Zhao; Jinming Zhang; Shuoqi Zhang; Huan Liu; Rujuan Xie; Jialan Shi
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

4.  Nitric oxide inhibits glomerular TGF-beta signaling via SMOC-1.

Authors:  Ellen Dreieicher; Karl-Friedrich Beck; Sandra Lazaroski; Meike Boosen; Wasiliki Tsalastra-Greul; Martina Beck; Ingrid Fleming; Liliana Schaefer; Josef Pfeilschifter
Journal:  J Am Soc Nephrol       Date:  2009-07-02       Impact factor: 10.121

Review 5.  Secreted modular calcium-binding proteins in pathophysiological processes and embryonic development.

Authors:  Qiang Gao; Hsiao-Pei Mok; Jian Zhuang
Journal:  Chin Med J (Engl)       Date:  2019-10-20       Impact factor: 2.628

6.  Anti-interleukin-33 Reduces Ovalbumin-Induced Nephrotoxicity and Expression of Kidney Injury Molecule-1.

Authors:  Geun Ho Park; Helen Ki Shinn; Ju-Hee Kang; Won Ju Na; Young Hyo Kim; Chang-Shin Park
Journal:  Int Neurourol J       Date:  2016-06-24       Impact factor: 2.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.